Moreover, the combination treatment of triciribine and cisplatin achieved synergistic anti-tumor activities and induced cervical cancer regression, which suggested that triciribine potentially sensitized cisplatin chemotherapy efficacy in ZNF275-expressing cervical cancer PDX models. This evidence concerns the gene ZNF275 and cervical carcinoma.